Organon's insomnia compound Org 50081 moves into phase III clinical trials
Willem de Laat, executive vice-president medical affairs at Organon said "Investigated dosages of the Org 50081 compound showed positive and robust results on multiple sleep parameters such as total sleep time and wakefulness after sleep onset. A statistically significant shorter time to sleep onset was demonstrated in Org 50081 treatment groups compared to placebo."
The Serotonin-2 blockade of Org 50081 is unique for an insomnia drug, according to the company. Unlike most other insomnia drugs, which work by interacting with the GABA receptors and thus have a potential risk for dependency, Org 50081's action is on the serotonergic and histaminergic systems. As such, while Org 50081 may improve both sleep initiation and sleep maintenance it is not likely to cause dependency.
Org 50081 is currently in Phase III development for two major indications: insomnia and menopausal symptoms (hot flashes).
Most read news
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.